Sun Pharma Q4 net up 23 percent, beats estimate
MUMBAI (Reuters) - Sun Pharmaceutical Industries(SUN.NS) reported a 23.4 percent rise in quarterly net profit beating market estimates, and India's top drugmaker by market value also announced a bonus share issue.
The Mumbai-based company said consolidated net profit rose to 10.12 billion rupees for the fourth quarter ended March 31, compared with 8.2 billion rupees a year earlier. Sales rose 31.8 percent to 30.71 billion rupees.
Analysts, on an average, had expected the company to post net profit of 9.07 billion rupees on net sales of 29.85 billion rupees, according to Thomson Reuters I/B/E/S.
The company also announced a one-for-one issue of bonus shares.
Shares of Sun Pharma, which has a market value of about $18.81 billion, fell 1.72 percent to 996.25 rupees on Tuesday, while the broader market gained 0.65 percent on the day. The stock has risen nearly 38 percent this year outperforming the benchmark index which has gained about 4 percent.
(Reporting by Kaustubh Kulkarni; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
- Missouri grand jury makes decision in fatal shooting of black teen
- Sting takes bold gamble to save his 'Last Ship' musical
- Cold hard facts: Underwater robot measures Antarctic sea ice |
- Cold hard facts: Underwater robot measures Antarctic sea ice
- Hagel move not seen scuttling efforts on innovation, warships
The reformist government that many Indians and free-market flag-bearers had hoped would emerge after this year's election isn't in New Delhi - at least not yet. Rajasthan, derided as a poverty-stricken laggard, has taken the lead on structural reforms that, their backers argue, could also help Asia's No.3 economy as a whole to attract business and employ a fast-growing workforce. Full Article
Hyundai Motor, Kia Motors lift 2014 global sales target on China, emerging markets Full Article